Oxymorphone-3-methoxynaltrexonazine
Oxymorphone-3-methoxynaltrexonazine is a synthetic opioid analgesic derived from oxymorphone. It is a potent agonist of the mu-opioid receptor and is used primarily for the management of severe pain. This compound is notable for its high affinity and selectivity for opioid receptors, which makes it a subject of interest in both clinical and research settings.
Chemical Structure and Properties[edit]
Oxymorphone-3-methoxynaltrexonazine is chemically related to oxymorphone and naltrexone. The addition of a methoxy group at the 3-position of the naltrexonazine structure significantly alters its pharmacological profile. The molecular formula of oxymorphone-3-methoxynaltrexonazine is C_19H_21NO_4.
Pharmacology[edit]
As an opioid agonist, oxymorphone-3-methoxynaltrexonazine exerts its effects primarily through the activation of the mu-opioid receptor. This receptor is part of the opioid receptor family, which also includes the delta-opioid receptor and the kappa-opioid receptor. Activation of the mu-opioid receptor leads to analgesia, euphoria, and respiratory depression, among other effects.
Medical Uses[edit]
Oxymorphone-3-methoxynaltrexonazine is used in the treatment of severe pain that is unresponsive to other analgesics. It is particularly useful in cases where patients have developed tolerance to other opioids. Due to its potency, it is typically administered in a controlled medical setting.
Side Effects[edit]
Common side effects of oxymorphone-3-methoxynaltrexonazine include nausea, vomiting, constipation, and drowsiness. More serious side effects can include respiratory depression, hypotension, and potential for addiction and abuse. As with other opioids, careful monitoring is required to manage these risks.
Regulation and Legal Status[edit]
Due to its high potential for abuse and addiction, oxymorphone-3-methoxynaltrexonazine is classified as a Schedule II controlled substance in many jurisdictions. This classification indicates that while it has accepted medical uses, it also carries a high risk of dependence and abuse.
Research[edit]
Ongoing research is focused on developing analogs of oxymorphone-3-methoxynaltrexonazine with improved safety profiles and reduced potential for abuse. Studies are also exploring its efficacy in treating other conditions, such as neuropathic pain and cancer pain.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
